Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

PLUVICTO

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

Standard Dose
27mCi/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview PLUVICTO is listed in Drugs@FDA under application 215833 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Form and strength SOLUTION;INTRAVENOUS - 27mCi/ML Sponsor NOVARTIS Submission history Latest submission status date: 2025-03-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview PLUVICTO is listed in Drugs@FDA under application 215833 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Form and strength SOLUTION;INTRAVENOUS - 27mCi/ML Sponsor NOVARTIS Submission history Latest submission status date: 2025-03-28 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.